Banco Santander S.A. Cuts Position in Boston Scientific Co. (NYSE:BSX)

Banco Santander S.A. decreased its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 40.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 16,703 shares of the medical equipment provider's stock after selling 11,421 shares during the period. Banco Santander S.A.'s holdings in Boston Scientific were worth $1,492,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of BSX. Bank Julius Baer & Co. Ltd Zurich boosted its holdings in shares of Boston Scientific by 0.5% during the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 291,426 shares of the medical equipment provider's stock valued at $27,557,000 after acquiring an additional 1,316 shares in the last quarter. Edgestream Partners L.P. acquired a new stake in shares of Boston Scientific during the 4th quarter valued at $2,064,000. Ashton Thomas Private Wealth LLC boosted its holdings in shares of Boston Scientific by 2.3% during the 4th quarter. Ashton Thomas Private Wealth LLC now owns 5,945 shares of the medical equipment provider's stock valued at $531,000 after acquiring an additional 136 shares in the last quarter. Callan Family Office LLC acquired a new stake in shares of Boston Scientific during the 4th quarter valued at $768,000. Finally, Hartford Funds Management Co LLC lifted its holdings in Boston Scientific by 6.9% during the 4th quarter. Hartford Funds Management Co LLC now owns 6,548 shares of the medical equipment provider's stock worth $585,000 after buying an additional 425 shares during the period. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Up 0.9 %

Boston Scientific stock traded up $0.90 during midday trading on Wednesday, reaching $96.42. The stock had a trading volume of 8,790,888 shares, compared to its average volume of 5,773,224. Boston Scientific Co. has a 12 month low of $65.52 and a 12 month high of $107.17. The company has a market capitalization of $142.29 billion, a P/E ratio of 77.14, a PEG ratio of 2.79 and a beta of 0.77. The company has a fifty day moving average price of $100.80 and a two-hundred day moving average price of $91.52. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Remove Ads

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, equities analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on BSX shares. Truist Financial lifted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. UBS Group lifted their target price on Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Barclays lifted their target price on Boston Scientific from $111.00 to $118.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Stifel Nicolaus lifted their target price on Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Finally, JPMorgan Chase & Co. lifted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an "overweight" rating in a report on Monday, December 16th. Two equities research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $108.91.

Insiders Place Their Bets

In other Boston Scientific news, EVP John Bradley Sorenson sold 1,201 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $106.31, for a total transaction of $127,678.31. Following the completion of the sale, the executive vice president now directly owns 25,443 shares of the company's stock, valued at approximately $2,704,845.33. The trade was a 4.51 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 12,000 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $105.48, for a total value of $1,265,760.00. Following the sale, the director now directly owns 24,398 shares of the company's stock, valued at $2,573,501.04. This represents a 32.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 137,302 shares of company stock valued at $14,319,269. Corporate insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.